Isoindolone derivative QSN-10c induces leukemic cell apoptosis and suppresses angiogenesis via PI3K/AKT signaling pathway inhibition
查看参考文献47篇
文摘
|
Aim: 2-(4,6-Dimethoxy-1,3-dioxoisoindolin-2-yl) ethyl 2-chloroacetate (QSN-10c) is one of isoindolone derivatives with antiproliferative activity against human umbilical vein endothelial cells (HUVECs). The aim of this study was to investigate its antitumor activity in vitro and anti-angiogenic effects in vitro and in vivo. Methods: K562 leukemic cells and HUVECs were used for in vitro studies. Cell viability was examined using MTT assay. Cell apoptosis and mitochondrial transmembrane potential (Δψm) were detected with flow cytometry. Tube formation and migration of HUVECs were studied using two-dimensional Matrigel assay and wound-healing migration assay, respectively. VEGF levels were analyzed with RT-PCR and Western blotting. A zebrafish embryo model was used for in vivo anti-angiogenic studies. The molecular mechanisms for apoptosis in K562 cells and antiangiogenesis were measured with Western blotting. Results: In antitumor activity studies, QSN-10c suppressed the viability of K562 cells and induced apoptosis in dose- and timedependent manners. Furthermore, QSN-10c dose-dependently decreased the Δψm in K562 cells, increased the release of cytochrome c and the level of Bax, and decreased the level of Bcl-2, suggesting that QSN-10c-induced apoptosis of K562 cells was mediated via the mitochondrial apoptotic pathway. In anti-angiogenic activity studies, QSN-10c suppressed the viability of HUVECs and induced apoptosis in dose dependent manners. QSN-10c treatment did not alter the Δψm in HUVECs, but dose-dependently inhibited the expression of VEGF, inhibited the tube formation and cell migration in vitro, and significantly suppressed the number of ISVs in zebrafish embryos in vivo. Furthermore, QSN-10c dose-dependently suppressed the phosphorylation of AKT and GSK3β in both HUVECs and K562 cells. Conclusion: QSN-10c is a novel antitumor compound that exerts both antitumor and anti-angiogenic effects via inhibiting the PI3K/ AKT/GSK3β signaling pathway. |
来源
|
Acta Pharmacologica Sinica
,2014,35(5):625-635 【核心库】
|
DOI
|
10.1038/aps.2013.194
|
关键词
|
isoindolone
;
anticancer drug
;
leukemia
;
zebrafish
;
angiogenesis
;
apoptosis
;
AKT
;
GSK3β
|
地址
|
1.
Department of Pharmacy, General Hospital of Shenyang Military Area Command, Shenyang, 110840
2.
Shenyang Pharmaceutical University, Shenyang, 110016
|
语种
|
英文 |
文献类型
|
研究性论文 |
ISSN
|
1671-4083 |
学科
|
医药、卫生;基础医学 |
文献收藏号
|
CSCD:5142653
|
参考文献 共
47
共3页
|
1.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease.
Nat Med,1995,1:27-31
|
CSCD被引
269
次
|
|
|
|
2.
Carmeliet P. Angiogenesis in cancer and other diseases.
Nature,2000,407:249-257
|
CSCD被引
338
次
|
|
|
|
3.
Padro T. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Blood,2000,95:2637-2644
|
CSCD被引
41
次
|
|
|
|
4.
Negaard H F. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.
Leukemia,2009,23:162-169
|
CSCD被引
15
次
|
|
|
|
5.
Li W W. Antiangiogenesis in haematological malignancies.
Br J Haematol,2008,143:622-631
|
CSCD被引
6
次
|
|
|
|
6.
Tosetti F. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents.
FASEB J,2002,16:2-14
|
CSCD被引
12
次
|
|
|
|
7.
El Sayed K A. Natural products as angiogenesis modulators.
Mini Rev Med Chem,2005,5:971-993
|
CSCD被引
1
次
|
|
|
|
8.
Papetti M. Mechanisms of normal and tumor-derived angiogenesis.
Am J Physiol Cell Physiol,2002,282:C947-C970
|
CSCD被引
21
次
|
|
|
|
9.
Ciccarelli M. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis.
Br J Pharmacol,2008,153:936-946
|
CSCD被引
2
次
|
|
|
|
10.
Hanahan D. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell,1996,86:353-364
|
CSCD被引
284
次
|
|
|
|
11.
Folkman J. Fundamental concepts of the angiogenic process.
Curr Mol Med,2003,3:643-651
|
CSCD被引
22
次
|
|
|
|
12.
Ferrara N. Angiogenesis as a therapeutic target.
Nature,2005,438:967-974
|
CSCD被引
86
次
|
|
|
|
13.
Semenza G L. HIF-1: using two hands to flip the angiogenic switch.
Cancer Metastasis Rev,2000,19:59-65
|
CSCD被引
10
次
|
|
|
|
14.
Millauer B. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.
Cell,1993,72:835-846
|
CSCD被引
31
次
|
|
|
|
15.
Wu L W. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation.
J Biol Chem,2000,275:5096-5103
|
CSCD被引
9
次
|
|
|
|
16.
Fujio Y. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner.
J Biol Chem,1999,274:16349-16354
|
CSCD被引
11
次
|
|
|
|
17.
Shiojima I. Role of Akt signaling in vascular homeostasis and angiogenesis.
Circ Res,2002,90:1243-1250
|
CSCD被引
27
次
|
|
|
|
18.
Rousseau S. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells.
Oncogene,1997,15:2169-2177
|
CSCD被引
13
次
|
|
|
|
19.
Lv W W. Isoindolones from Lasiosphaera fenzlii Reich and their bioactivities.
Helv Chim Acta,2013,96:109-113
|
CSCD被引
4
次
|
|
|
|
20.
Qin S N. Design, synthesis and biological evaluation of N-substituted phthalimide derivative.
Chem J Chinese U,2013,34:2745-2751
|
CSCD被引
2
次
|
|
|
|
|